Description
Cagrilintide at a glance
Cagrilintide is a long-acting, lipidated analogue of amylin, a pancreatic hormone. It is studied in obesity and type 2 diabetes research, most visibly within CagriSema, its pairing with semaglutide. Ellepeptides supplies cagrilintide on its own as freeze-dried research material in 5 mg and 10 mg vials, listed in our weight management research collection.
- Molecule type: lipidated amylin analogue, 37 amino acids
- Vial sizes: 5 mg and 10 mg
- Listed price: from $74.45 USD
- Form: freeze-dried (lyophilized) powder
- Ships within the United States; free shipping when the merchandise subtotal is over $200
- For laboratory research only
Cagrilintide vial sizes and price per mg
| Vial size | Listed price (USD) | Price per mg |
|---|---|---|
| 5 mg | $74.45 | $14.89 |
| 10 mg | $170.00 | $17.00 |
Prices are listed in USD at the time of writing; the size selector above shows the current price. Bulk or combination savings through the cart or coupons are not promised.
Cagrilintide compound profile
| Research name | Cagrilintide (development code NNC0174-0833) |
|---|---|
| Compound class | Lipidated amylin analogue |
| Peptide length | 37 amino acids |
| Reference molecular formula | C194H312N54O59S2 |
| Reference molar mass | 4409 g/mol |
| CAS number | 1415456-99-3 |
| PubChem record | CID 171397054 |
The table describes the reference cagrilintide molecule, not the analytical make-up of any lot. Salt form and water content can differ between materials; read the vial label and any documentation supplied.
How cagrilintide works in research
Amylin analogues are not new: pramlintide came first, and the cagrilintide development paper notes the short half-life that limited that earlier molecule. Cagrilintide was engineered as the answer, a stable, lipidated, long-acting amylin analogue built on an amylin-based sequence with an attached lipid group. Kruse et al. (2021)
Amylin signals through a small receptor family. The calcitonin receptor can act alone or pair with accessory proteins to form three amylin receptor subtypes. A 2025 structural study mapped cagrilintide bound to all three amylin receptor types and to the calcitonin receptor. It found an amylin-like binding pattern with distinct receptor movements, a molecular explanation for activity at both receptor families. Cao et al. (2025)
This profile separates cagrilintide from semaglutide, which acts on the GLP-1 receptor instead. CagriSema pairs the two pathways, so the combination trials below test the pairing rather than cagrilintide by itself.
Key cagrilintide studies
| Year | Study & model | What was measured | Main finding | Source |
|---|---|---|---|---|
| 2021 | Phase 1b; given with semaglutide | Pharmacokinetics and safety | Cagrilintide half-life of 159–195 hours during co-administration | Enebo et al. |
| 2021 | Phase 2; 706 adults with overweight or obesity, no diabetes; 26 weeks | Weight change vs placebo | 6.0% to 10.8% across cagrilintide arms vs 3.0% with placebo; more gastrointestinal events | Lau et al. |
| 2023 | Phase 2; 92 adults with type 2 diabetes; 32 weeks | Body-weight change | −15.6% CagriSema, −5.1% semaglutide, −8.1% cagrilintide | Frias et al. |
| 2025 | REDEFINE 1; overweight or obesity without diabetes; 68 weeks | Weight change, CagriSema vs placebo | −20.4% vs −3.0% | Garvey et al. |
| 2025 | REDEFINE 2; type 2 diabetes with overweight or obesity; 68 weeks | Weight change, CagriSema vs placebo | −13.7% vs −3.4% | Davies et al. |
| 2026 | REDEFINE 4 sponsor topline; CagriSema vs tirzepatide; 84 weeks | Body-weight change | −20.2% vs −23.6%; noninferiority objective not met | Novo Nordisk |
| 2026 | REIMAGINE 2; phase 3, adults with type 2 diabetes | CagriSema vs its components and placebo | Published, then corrected; numbers not summarized here | Buse et al.; correction |
The only large cagrilintide-alone trial. The 2021 phase 2 study is the main evidence for cagrilintide on its own. Its 6.0–10.8% range comes from the analysis that assumed participants kept taking the trial product, and gastrointestinal adverse events were more common than with placebo. Lau et al. (2021)
Combination results are not cagrilintide results. The 2023 study and REDEFINE 1 and 2 measured CagriSema; REDEFINE analyses also counted participants who stopped treatment. REDEFINE 4 figures come from a February 2026 sponsor announcement, a lower evidence level than peer review. Our research page explains how we grade sources.
REIMAGINE 2: published study and correction. This randomized, double-blind phase 3 trial in adults with type 2 diabetes compared CagriSema with its components and placebo. The journal later published a correction, and the linked PubMed notice does not describe what changed, so numerical outcomes are not summarized here. Buse et al. (2026); published correction
Cagrilintide research involving women
Women made up most of the phase 2 population: the official results register records 436 women among the 706 participants. That confirms substantial inclusion, but the published weight results are pooled across sexes, not a women-only analysis. EU Clinical Trials Register
The sources here do not report cagrilintide effects on menstrual cycles, fertility, pregnancy or menopause, so no claim about female hormones follows from them. For other compounds with women-specific study notes, see our peptides for women hub.
Cagrilintide vs semaglutide, tirzepatide and retatrutide
| Compound | Type | Main research focus | Sizes on Ellepeptides |
|---|---|---|---|
| Cagrilintide (this page) | Lipidated amylin analogue | Amylin and calcitonin receptor signaling; CagriSema trials | 5 mg, 10 mg |
| Semaglutide | GLP-1 receptor agonist | Glucose control and body weight | 5 mg, 10 mg, 20 mg, 30 mg |
| Tirzepatide | GIP and GLP-1 receptor agonist | Glucose control and body weight | 10 mg, 15 mg, 20 mg, 30 mg, 60 mg |
| Retatrutide | GIP, GLP-1 and glucagon receptor agonist | Body weight and metabolic measures | 5 mg, 10 mg, 30 mg, 50 mg, 60 mg |
Cagrilintide is the only amylin-pathway compound in this group; the other three act on incretin receptors. That is why it is usually studied alongside semaglutide, and why REDEFINE 4 tested CagriSema, not cagrilintide alone, against tirzepatide.
Cagrilintide handling, storage and reconstitution math
Cagrilintide is supplied as a dry, lyophilized solid. The vial label is the reference for the stated amount and for storage conditions; keep the vial sealed until your protocol calls for it and note the lot number in your records. Its lipid side chain means notes written for short, unmodified peptides may not apply.
Concentration is vial mass divided by solvent volume: 2 mL added to a 5 mg vial gives 2.5 mg/mL, and to a 10 mg vial, 5 mg/mL. The peptide calculator does the arithmetic. Labs that sample one vial repeatedly often use bacteriostatic water; use whichever solvent your method specifies.
Ordering cagrilintide in the US
Cagrilintide orders ship to addresses within the United States. Shipping is free when your merchandise subtotal is over $200 after coupon discounts (before taxes and shipping); below that, standard shipping is $15.99 per order. The available payment methods and delivery options are shown at checkout, so check the shipping policy for current details.
Cagrilintide FAQ
What is cagrilintide?
Cagrilintide is a synthetic, long-acting amylin analogue: a 37-amino-acid peptide with an attached lipid group. Structural work shows it binds all three amylin receptor subtypes and the calcitonin receptor. Ellepeptides sells it alone as freeze-dried research material in 5 mg and 10 mg vials.
How much does cagrilintide cost in the US?
At the time of writing, Ellepeptides lists cagrilintide at $74.45 USD for 5 mg ($14.89 per mg) and $170.00 USD for 10 mg ($17.00 per mg). The size selector always shows the current price. Shipping is free when the merchandise subtotal is over $200 after coupons.
Where can I buy cagrilintide in the US for research?
Ellepeptides lists cagrilintide research vials and ships them to US addresses, with prices in USD and payment methods shown at checkout. It is sold for laboratory research only; current rates are in the shipping policy.
What is CagriSema?
CagriSema is the investigational combination of cagrilintide and semaglutide developed by Novo Nordisk. In REDEFINE 1, adults with overweight or obesity without diabetes had an estimated −20.4% weight change at 68 weeks versus −3.0% with placebo. This listing contains cagrilintide only, not the combination.
Cagrilintide vs semaglutide: what is the difference?
They act on different receptors. Cagrilintide is an amylin analogue that binds amylin and calcitonin receptors; semaglutide is a GLP-1 receptor agonist. In a 2023 phase 2 study in type 2 diabetes, the cagrilintide arm averaged −8.1% and the semaglutide arm −5.1% at 32 weeks; the pairing averaged −15.6%.
What side effects of cagrilintide were reported in studies?
In the 26-week phase 2 trial of 706 adults, gastrointestinal adverse events were more common with cagrilintide than with placebo. Those observations apply to the clinical materials and populations studied. They are not a safety profile for a research vial, which is not for human or veterinary use.
What is the half-life of cagrilintide?
A 2021 phase 1b study reported a cagrilintide half-life of 159–195 hours when it was given together with semaglutide. That is a study-specific pharmacokinetic measurement in people. It is not a shelf life, a storage interval or an instruction for handling a research vial.
Does this cagrilintide vial contain semaglutide?
No. This listing is cagrilintide alone; the 5 mg or 10 mg figure is the nominal amount of one compound, not a blend ratio. Semaglutide is listed separately. Results from CagriSema studies therefore cannot be assigned to cagrilintide by itself.
Is cagrilintide available as a pill or nasal spray?
Ellepeptides sells cagrilintide only as freeze-dried powder in sealed vials. The trials cited on this page used the sponsor’s own clinical preparations, and none of them tested a capsule or nasal spray version. Findings from those studies cannot be assumed to apply to another form.
How should cagrilintide vials be stored?
Follow the storage conditions printed on the vial label and any documentation supplied with your order. Published trials do not set storage rules for research material. For any detail the label does not answer, such as lot information, email [email protected].
Cagrilintide references
- National Library of Medicine, PubChem. Cagrilintide, CID 171397054.
- Kruse T, et al. (2021). Cagrilintide development. PubMed 34288673.
- Cao J, et al. (2025). Receptor structures. PMC11982234.
- Lau DCW, et al. (2021). Phase 2 trial. PubMed 34798060.
- EU Clinical Trials Register. Trial 2018-001945-14 results. Register record.
- Enebo LB, et al. (2021). Phase 1b study. PubMed 33894838.
- Frias JP, et al. (2023). CagriSema phase 2 study. PubMed 37364590.
- Garvey WT, et al. (2025). REDEFINE 1. PubMed 40544433.
- Davies MJ, et al. (2025). REDEFINE 2. PubMed 40544432.
- Novo Nordisk (2026). REDEFINE 4 topline announcement. Company release.
- Buse JB, et al. (2026). REIMAGINE 2. PubMed 42251859.
- Published correction to REIMAGINE 2 (2026). PubMed 42320507.
Related research materials: Weight Management, all research peptides, peptides for women, Semaglutide, Tirzepatide and Retatrutide. For laboratory research only. Not for human or veterinary use.
Reviews
There are no reviews yet.